# Ensysce Biosciences, Inc. (ENSCW) — merger/scheme_of_arrangement [announced]
Source: sec.gov · situation sit_0d2362cb0d7d20ead225 · public 6449448689694816081 · retrieved 2026-08-19T11:57:41.967Z

## Overview
Ensysce Biosciences, Inc. is a pharmaceutical company developing abuse-deterrent opioid formulations and other controlled-release drug products.

On April 23, 2026, Bob Gene Gower (Chairman of Ensysce Biosciences, Inc.) converted outstanding convertible promissory notes with principal and accrued interest totaling $246,169 into 508,614 shares of Common Stock and a warrant to purchase 254,307 shares at an exercise price of $0.484 per share. On August 7, 2026, Gower purchased an additional 400,000 shares of Common Stock at $0.495 per share using personal funds of $198,000, which triggered the filing of this amended Schedule 13D. Following these transactions, Gower beneficially owns 1,206,576 shares (including 2,013 shares subject to options and 287,823 shares acquirable through warrant exercise), representing approximately 6.1% of the company's outstanding common stock as of August 12, 2026.

## Terms
- Consideration: mixed · Stake: 6.1% · Price/share: $0.495

## Key dates
- Announced 2026-08-18

## Timeline
- 2026-08-18 · SCHEDULE 13D/A (0001493152-26-038943): SCHEDULE 13D/A - Ensysce Biosciences, Inc. — *Ensysce Biosciences, Inc. is a pharmaceutical company developing abuse-deterrent opioid formulations and other controlled-release drug products.* On April 23, 2026, Bob Gene Gower (Chairman of Ensysce Biosciences, Inc.) converted outstanding convertible promissory notes with principal and accrued interest totaling $246,169 into 508,614 shares of Common Stock and a warrant to purchase 254,307 shares at an exercise price of $0.484 per share. On August 7, 2026, Gower purchased an additional 400,000 shares of Common Stock at $0.495 per share using personal funds of $198,000, which triggered the filing of this amended Schedule 13D. Following these transactions, Gower beneficially owns 1,206,576 shares (including 2,013 shares subject to options and 287,823 shares acquirable through warrant exercise), representing approximately 6.1% of the company's outstanding common stock as of August 12, 2026.
  https://www.sec.gov/Archives/edgar/data/1716947/0001493152-26-038943.txt

## Citations
- 0001493152-26-038943 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226038943